A wide-ranging survey by Europe’s research-based pharma industry says moves towards replacing paper product information are gathering pace, although numerous challenges will need to be overcome.
Full implementation of electronic product information (ePI) on medicines in the EU may not be achieved until 2030, according to a survey conducted by the European R&D-based pharmaceutical industry federation, EFPIA.
As part of the shift to ePI, a pilot scheme in Belgium and Luxembourg on switching from paper to electronic...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
